Ribomic Inc. (4591.T)
JPY 80.0
(0.0%)
JPY 80.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.1 Billion JPY | -39.73% |
| 2022 | 1.85 Billion JPY | 1.26% |
| 2021 | 1.82 Billion JPY | 37.35% |
| 2020 | 1.33 Billion JPY | 36.57% |
| 2019 | 975 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 258 Million JPY | -9.97% |
| 2023 Q1 | 338.22 Million JPY | 0.58% |
| 2023 Q2 | 243.57 Million JPY | -27.98% |
| 2023 Q4 | 286.58 Million JPY | 15.65% |
| 2023 Q3 | 247.8 Million JPY | 1.74% |
| 2023 FY | 1.11 Billion JPY | -39.73% |
| 2022 Q3 | 584.79 Million JPY | 97.38% |
| 2022 FY | 1.85 Billion JPY | 1.26% |
| 2022 Q4 | 336.26 Million JPY | -42.5% |
| 2022 Q2 | 296.28 Million JPY | 0.0% |
| 2021 FY | 1.82 Billion JPY | 37.35% |
| 2020 FY | 1.33 Billion JPY | 36.57% |
| 2019 FY | 975 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 13.919% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -91.689% |
| GNI Group Ltd. | 9.32 Billion JPY | 88.139% |
| Linical Co., Ltd. | 2.7 Billion JPY | 59.127% |
| Trans Genic Inc. | 2.15 Billion JPY | 48.807% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 25.85% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 63.997% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 40.457% |
| AnGes, Inc. | 8.9 Billion JPY | 87.58% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -17.242% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 94.238% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -167.728% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -13.361% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 56.936% |
| CanBas Co., Ltd. | 278 Million JPY | -297.731% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 3.14% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 39.179% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 31.056% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 53.426% |
| PeptiDream Inc. | 9.68 Billion JPY | 88.586% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 43.604% |
| SanBio Company Limited | 4.53 Billion JPY | 75.64% |
| Healios K.K. | 3.48 Billion JPY | 68.291% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 4.247% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 17.143% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 21.217% |
| StemRIM | 2.07 Billion JPY | 46.739% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 43.688% |
| FunPep Company Limited | 313.82 Million JPY | -252.332% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -15.415% |
| Stella Pharma Corporation | 963.98 Million JPY | -14.7% |
| TMS Co., Ltd. | 943.25 Million JPY | -17.221% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -1.444% |
| Cuorips Inc. | 598.11 Million JPY | -84.862% |
| K Pharma,Inc. | 543.94 Million JPY | -103.274% |
| Takara Bio Inc. | 23.9 Billion JPY | 95.375% |
| ReproCELL Incorporated | 1.51 Billion JPY | 26.97% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 6.613% |
| StemCell Institute Inc. | 1.16 Billion JPY | 4.856% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 27.366% |
| CellSeed Inc. | 804.93 Million JPY | -37.365% |